Failures halt Phase III trials of infused Alzheimer's drug

Share this article:
Failures halt Phase III trials of infused Alzheimer's drug
Failures halt Phase III trials of infused Alzheimer's drug
Pfizer, Johnson & Johnson, and Elan said all Phase III tests of Alzheimer's drug bapineuzumab are being halted after the drug failed to hit its goals for cognition and global function.

The Phase III tests involved the infusion form of the drug and were being conducted among patients with mild to severe forms of the neurological disease. The August announcement came 15 days after the companies said the drug also had failed to hit goals in another Phase III trial.

With bapineuzumab, along with Eli Lilly's own Alzheimer's candidate solanezumab, considered long shots by many, the immediate fallout of the news has been little more than a shrug. Sanford Bernstein analyst Tim Anderson wrote in a research note that he never even bothered to front-load Pfizer forecasts with the possibility that bapineuzumab could become viable.

The drug is not completely dead, however. Pfizer said its Phase II studies with ACC-001 (active immunization) and a Phase II neuroimaging study, called SUMMIT (bapineuzumab delivered subcutaneously), remain up and running.

Anderson speculated that Pfizer's Phase II commitment may signal interest in using the drug as a preventive treatment among patients who are symptom-free. Such a tack would put bapineuzumab into direct competition with an approach Genentech and AC Immune are pursuing to fight the disease, albeit via a different mechanism.

Genentech's approach targets tau proteins, unlike bapineuzumab, which targets beta amyloid protein, which are associated with brain plaques that are linked to the disease.

Moving forward, Lilly has yet to announce Phase III results on solanezumab. Leerink Swann's Seamus Fernandez wrote that he put the odds of a successful Phase III trial for solanezumab at less than 5%. He also wrote that bapineuzumab's failure only enhanced his low expectations for the drug becoming any sort of contender.
Share this article:
close

Next Article in News

More in News

Expert says providers often wrongly threatened by PEPPER reports

Instead of fearing further scrutiny by federal authorities, providers should embrace the opportunity to get feedback in the form of PEPPER reports, legal experts said Monday at the LeadingAge annual meeting in Nashville.

Healthcare reform already driving diverse, dynamic long-term care models, LeadingAge leaders say

Healthcare reform already driving diverse, dynamic long-term care ...

One way to gauge the effects is healthcare reform is by looking at ongoing changes to the continuing care retirement community model, LeadingAge officials said Monday at the association's annual ...

Federal court: Nursing home can be sued for firing hairdresser who can ...

Is the ability to transport residents in their wheelchairs an essential function of a nursing home hairdresser? A federal appeals court says it's a valid question and is allowing a hairdresser to sue a facility that fired her.